Krystal Biotech Buys Back Its Own Story While the Pipeline Slips Into 2027
A $400M repurchase lands precisely when the readouts it was supposed to depend on move right — and a three-patient Gorlin pilot becomes the only thing that got better.
KRYS · Earnings Call · 2026-11-02
Krystal Biotech Buys Back Its Own Story While the Pipeline Slips Into 2027
VYJUVEK crossed $1.1 billion of lifetime revenue this quarter. The pipeline crossed into 2027. Both facts arrived in the same press release, and the market has spent four months repricing the second one.
The buyback they spent four quarters deferring
For at least a year, Krystal's capital-allocation answer was a conditional, not a decision. In February 2026, Krish Krishnan framed it this way:
we understand we have a few research programs you know our pipeline... until we kind of have a better sense of how those larger indications are gonna go... It is difficult to be very definitive on a timeline for a stock buyback.
By May the condition had been named with unusual precision — the trigger was supposed to be pipeline visibility: “once we have visibility into the future of our pipeline, especially on the drugs that address large markets, KB408, the oncology, the aesthetics... that would be a great timing to think about share buyback.” — Krish Krishnan, Chief Executive Officer (CEO) or Founder · 2026-05-04
So note what actually happened. On this call the board authorized up to $400 million of repurchase — roughly a third of the $1.2 billion cash and investments stack, and about 4.6% of an $8.8 billion market cap — in the same breath as management pushed out KB408, KB801, KB407 and Hailey-Hailey. Visibility did not improve. It degraded. The justification shifted accordingly, from pipeline de-risking to intrinsic value: “We also internally believe that the intrinsic value of the what the stock value is and what we believe is intrinsic value are dislocated at the moment.” — Krish S. Krishnan, Chief Executive Officer (CEO) · 2026-11-02 That is a defensible read of a stock sitting 21.8% below its June 29 peak of $378.15, down 20.5% over ninety trading days. It is also a different argument than the one they made in May.
The buyback is the single genuinely new item in this report — new enough that it has its own keyword this quarter after four straight calls of deferral. Everything else is a re-timing.
Gorlin: small, weird, and the best thing on the call
The exception is KB113. Three adult Gorlin syndrome patients, six intratumoral doses over fourteen weeks, and a result that reads more like a case series from a different company: “over 80% of the assessed lesions regressed over the course of the study, and more than half of all lesions regressed by over 50%” — Suma Krishnan, Chief Medical Officer (CMO) · 2026-11-02 — with roughly 10% of assessed tumors shrinking by at least 90%, regression in never-injected lesions (an abscopal signal), and complete histological clearance confirmed in one biopsied lesion per patient. Suma Krishnan did not hide her surprise: “I mean, as you can see from a 3 patient study where we looked at it, the data was pretty remarkable.” — Suma Krishnan, Chief Medical Officer (CMO) · 2026-11-02
What matters analytically is that Gorlin is not new to this company's vocabulary — the intratumoral KB707 Gorlin formulation already surfaced in the keyword set back in 2024 — but it has never been a headline until the data forced it. There is no Gorlin, no basal-cell carcinoma burden, anywhere in the global market keyword set for this quarter. This is company-unique science, not a wave. Management's own sizing — a pivotal "well within less than 100 patients" — is the kind of claim you only make when the control arm is believably zero.
Where the momentum actually leaked
The Ocular DEB and NK programs are where the quarter's credibility gets tested. In August, Suma Krishnan was explicit about KB801 timing: “we are targeting and getting all of it enrolled by end of the year. So potentially '27 by the -- early '27 by the time we clean the database and announce data.” — Suma Krishnan, Chief Medical Officer · 2026-08-03 That was already a revision — in November 2025 Krishnan had set an internal target of interim NK data "by the middle of next year." Now the language has hardened into: “we now expect to complete the enrollment and report top-line results in 2027.” — Suma Krishnan, Chief Medical Officer (CMO) · 2026-11-02
The mechanism is more interesting than the delay. KB801 is failing screens, not for lack of interest but because of the company's own inclusion/exclusion criteria — a double-screening rule that disqualifies any patient whose corneal lesion shrinks at all between visits, precisely to protect the placebo comparison. Layer on academic-site contracting for a GMO product and 22 activated US sites, and you get the quarter's quietest admission: the trial is designed to be slow because it is designed to win. Ocular DEB's last-patient-last-visit is now February 2027.
And the spend guide moved the other way — non-GAAP R&D and SG&A cut to $155–165 million from $175–195 million. When Yigal Nochomovitz asked directly whether more money would buy faster enrollment, the answer was permissive but unspecific: anywhere additional investment "would immediately translate to either increasing enrollment, or conducting a faster study," they would do it. They did not do it.
The numbers underneath the narrative
Revenue quality remains genuinely good. VYJUVEK did $127.3 million, +30% year over year, split $95.3 million US and $32 million international, at 94% gross margin — two points lighter than last year purely because European and Japanese product does not yet benefit from the US-approved manufacturing optimization. Net income of $63.1 million and $2.05 diluted EPS is real cash, not accounting: last filed quarter showed free cash flow of $57 million, up 55% year over year. Against that, $400 million over two years is less than two years of organic cash — a comfortably funded signal, not a stretch.
Valuation has done most of the work for the bulls: 25.0x price to revenue is a long way from the 377.6x peak of 2023, and R&D at roughly 12% of revenue is the profile of a company that has stopped spending to discover and started spending to file.
The part nobody asked about
The most under-discussed item is international. Germany, Japan and Italy pricing are now concluded; Spain is expected before year end; France is a longer runway with a new committee chair and a stated thirteen-month framework. Meanwhile Japan's prescription restriction lifts in November or December — the exact compliance drag management walked investors through in February, now compressed into a single sentence. As the VYJUVEK revenue base broadens, the growth story is migrating from price negotiation to simple access logistics, which is a better place to be.
The setup into year end is therefore oddly bifurcated: a Hailey-Hailey readout before December that management has pre-committed to as the near-term catalyst, a Gorlin program that just earned a development plan, and a buyback that says the board thinks the equity is cheap. What it is not is a company whose pipeline got clearer. Krystal is paying shareholders to wait — and, for the first time, admitting the wait is longer than promised.